CeriBell (CBLL) Set to Post Quarterly Earnings on Tuesday

CeriBell (NASDAQ:CBLL) will likely be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect CeriBell to announce earnings of ($0.50) per share and revenue of $29.16 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, analysts expect CeriBell to post ($1.96) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

CeriBell Stock Down 0.4%

CBLL stock opened at $27.03 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock has a market capitalization of $1.04 billion, a P/E ratio of -15.36 and a beta of 0.94. CeriBell has a fifty-two week low of $10.85 and a fifty-two week high of $28.11. The business has a 50-day moving average of $24.70 and a 200-day moving average of $20.72.

Insiders Place Their Bets

In other news, VP David Foehr sold 9,255 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the sale, the vice president directly owned 34,144 shares of the company’s stock, valued at $827,992. The trade was a 21.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CRO Joseph S. Manni sold 1,361 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $32,691.22. Following the transaction, the executive directly owned 55,956 shares in the company, valued at $1,344,063.12. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 174,905 shares of company stock valued at $4,312,995 over the last three months. Insiders own 17.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CBLL shares. TD Cowen raised their price objective on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Friday, September 11th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.00.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.